As previously announced, BioInvent’s largest shareholder Van Herk Investments B.V. sold, due to an administrative error with the custodial bank, subscription rights corresponding to 3,193,312 shares instead of exercising these in BioInvent’s recent rights issue in accordance with a subscription undertaking. Van Herk Investments B.V. therefore undertook towards BioInvent to purchase, in a supervised manner, an equivalent number of shares in the market during a period estimated to amount to approximately sixty trading days. Van Herk Investments B.V. has now informed BioInvent that the said share purchase has been completed.

-- END –

To the editors:

About BioInvent
BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Les Laboratoires Servier and Mitsubishi Tanabe Pharma. More information is available at www.bioinvent.com.

For further information, please contact:
Michael Oredsson                                               
President and CEO                                             
+46 (0)46 286 85 67                                             
+46 (0)707 16 89 30
[email protected]

BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
[email protected]
www.bioinvent.com

Information disclosed in this press release is provided herein pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.50 a.m. CET, on 5 June, 2014.